Update on ultra-long-acting β agonists in chronic obstructive pulmonary disease

Expert Opinion on Investigational Drugs

Volumn 23, Issue 12, 2014, Pages 1687-1701

  Zafar, Muhammad Ahsan ^a,b   Droege, Christopher ^a   Foertsch, Madeline ^a   Panos, Ralph J ^a,b  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Chronic obstructive pulmonary disease; Long acting agonist; Ultra long acting agonist; agonist

Indexed keywords

ABEDITEROL; AZD 3199; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CARMOTEROL; GLUCOSE; INDACATEROL; LONG ACTING ANTI MUSCARINIC AGONIST; LONG ACTING BETA AGONIST; MILVETEROL; MUSCARINIC AGENT; OLODATEROL; PF 610355; PLACEBO; POTASSIUM; UNCLASSIFIED DRUG; VILANTEROL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT;

BLOOD PRESSURE; CHEMICAL STRUCTURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; COUGHING; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG SAFETY; ELECTROCARDIOGRAM; GLUCOSE BLOOD LEVEL; HEALTH CARE UTILIZATION; HEART DISEASE; HEART LEFT VENTRICLE FAILURE; HEART PALPITATION; HEART RATE; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; MEDICATION COMPLIANCE; MORTALITY; MUSCLE SPASM; POTASSIUM BLOOD LEVEL; RESPIRATORY TRACT DISEASE; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SURVIVAL; THROAT IRRITATION; TREMOR; ANIMAL; METABOLISM; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ANIMALS; BRONCHODILATOR AGENTS; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

EID: 84924416885     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.942730     Document Type: Review

References (108)

1. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2014. Available from: http://www.goldcopd.org/ guidelines-global-strategy-for-diagnosismanagement. html [Last accessed 12 May 2014]
2. Higgins BG, Powell RM, Cooper S, et al. Effect of salbutamol and ipratropium bromide on airway calibre and bronchial reactivity in asthma and chronic bronchitis. Eur Respir J 1991;4(4):415-20
3. O'Donnell DE, Flüge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004;23(6):832-40
4. O'Donnell DE, Sciurba F, Celli B, et al. Effect of fluticasone propionate/ salmeterol on lung hyperinflation and exercise endurance in COPD. Chest 2006;130(3):647-56
5. Billington CK, Ojo OO, Penn RB, et al. cAMP regulation of airway smooth muscle function. Pulm Pharmacol Ther 2013;26:112-20
6. Cazzola M, Page CP, Rogliani P, et al. β2-agonist therapy in lung disease. Am J Respir Crit Care Med 2013;187(7):690-6
7. Billington CK, Penn RB. Signaling and regulation of G protein-coupled receptors in airway smooth muscle. Respir Res 2003;4:2
8. Spina D. Current and novel bronchodilators in respiratory disease. Curr Opin Pulm Med 2014;20(1):73-86
9. Lin Y, Smrcka AV. Understanding molecular recognition by G protein betagamma subunits on the path to pharmacological targeting. Mol Pharmacol 2011;80(4):551-7
10. Roscioni SS, Maarsingh H, Elzinga CRS, et al. Epac as a novel effector of airway smooth muscle relaxation. J Cell Mol Med 2011;15:1551-63
11. Janssen LJ, Tazzeo T, Zuo J. Enhanced myosin phosphatase and Ca(2p)-uptake mediate adrenergic relaxation of airway smooth muscle. Am J Respir Cell Mol Biol 2004;30:548-54
12. Mahn K, Ojo OO, Chadwick G, et al. Ca(2+) homeostasis and structural and functional remodeling of airway smooth muscle in asthma. Thorax 2010;65(6):547-52
13. Sykes DA, Charlton SJ. Slow receptor dissociation is not a key factor in the duration of action of inhaled long-acting beta2-adrenoceptor agonists. Br J Pharmacol 2012;165:2672-83
14. Slack RJ, Barrett VJ, Morrison VS, et al. In vitro pharmacological characterization of vilanterol, a novel long acting beta2-adrenoceptor agonist with 24 hour duration of action. J Pharmacol Exp Ther 2013;344:218-30
15. Bouyssou T, Hoenke C, Rudolf K, et al. Discovery of olodaterol, a novel inhaled beta2-adrenoceptor agonist with a 24 h bronchodilatory efficacy. Bioorg Med Chem Lett 2010;20:1410-14
16. Rosethorne EM, Turner RJ, Fairhurst RA, et al. Efficacy is a contributing factor to the clinical onset of bronchodilation of inhaled beta(2)-adrenoceptor agonists. Naunyn Schmiedebergs Arch Pharmacol 2010;382:255-63
17. Lombardi D, Cuenoud B, Krämer SD. Lipid membrane interactions of indacaterol and salmeterol: do they influence their pharmacological properties? Eur J Pharm Sci 2009;38:533-47
18. Vauquelin G, Charlton SJ. Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action. Br J Pharmacol 2010;161:488-508
19. Anderson GP, Linden A, Rabe KF. Why are long-acting beta-adrenoceptor agonists long-acting? Eur Respir J 1994;7:569-78
20. Coleman RA. On the mechanism of the persistent action of salmeterol: what is the current position? Br J Pharmacol 2009;158(1):180-2
21. Green SA, Spasoff AP, Coleman RA, et al. Sustained activation of G protein-coupled receptor via "anchored" agonist binding. Molecular localization of the salmeterol exosite within the 2-adrenergic receptor. J Biol Chem 1996;271(39):24029-35
22. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356(8):775-89
23. Boyd G, Morice AH, Pounsford JC, et al. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J 1997;10(4):815-21
24. Cazzola M, Matera MG, Santangelo G, et al. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Respir Med 1995;89(5):357-62
25. Cazzola M, Santus P, Di Marco F, et al. Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD. Respir Med 2003;97(5):453-7
26. Barr RG, Bourbeau J, Camargo CA, et al. Inhaled tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005(2):CD002876
27. Santus P, Centanni S, Verga M, et al. Comparison of the acute effect of tiotropium versus a combination therapy with single inhaler budesonide/formoterol on the degree of resting pulmonary hyperinflation. Respir Med 2006;100(7):1277-81
28. Santus P, Buccellati C, Centanni S, et al. Bronchodilators modulate inflammation in chronic obstructive pulmonary disease subjects. Pharmacol Res 2012;66(4):343-8
29. Barr RG, Bourbeau J, Camargo CA, et al. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax 2006;61(10):854-62
30. Kesten S, Casaburi R, Kukafka D, et al. Improvement in self-reported exercise participation with the combination of tiotropium and rehabilitative exercise training in COPD patients. Int J Chron Obstruct Pulmon Dis 2008;3(1):127-36
31. Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011;364(12):1093-103
32. Chong J, Karner C, Poole P. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012;9:CD009157
33. Jones PW, Singh D, Bateman ED, et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J 2012;40(4):830-6
34. Vogelmeier CF, Bateman ED, Pallante J, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med 2013;1(1):51-60
35. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359(15):1543-54
36. Jones PW, Beeh KM, Chapman KR, et al. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med 2014;189(3):250-5
37. Cazzola M, MacNee W, Martinez FJ, et al. American Thoracic Society; European Respiratory Society Task Force on outcomes of COPD. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008;31:416-69
38. Chapman KR, Bergeron C, Bhutani M, et al. Do we know the minimal clinically important difference (MCID) for COPD exacerbations? COPD 2013;10(2):243-9
39. Battram C, Charlton SJ, Cuenoud B, et al. In. vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta (2) adrenoceptor agonist. with a 24-h duration of action. J Pharmacol Exp Ther 2006;317(2):762-70
40. Naline E, Trifilieff A, Fairhurst RA, et al. Effect of indacaterol, a novel long-acting beta2-agonist, on isolated human bronchi. Eur Respir J 2007;29(3):575-81
41. Feldman G, Siler T, Prasad N, et al. Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med 2010;10:11
42. Kerwin EM, Gotfried MH, Lawrence D, et al. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies. Clin Ther 2011;33(12):1974-84
43. Kinoshita M, Lee SH, Hang LW, et al. Efficacy and safety of indacaterol 150 and 300 μg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled study. Respirology 2012;17(2):379-89
44. Santus P, Radovanovic D, Henchi S, et al. Assessment of acute bronchodilator effects from specific airway resistance changes in stable COPD patients. Respir Physiol Neurobiol 2014;197:36-45
45. Dahl R, Chung KF, Buhl R, et al. INVOLVE (INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 2010;65:473-9
46. Korn S, Kerwin E, Atis S, et al. Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study. Respir Med 2011;105(5):719-26
47. Kornmann O, Dahl R, Centanni S, et al. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J 2011;37(2):273-9
48. Buhl R, Dunn LJ, Disdier C, et al. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur Respir J 2011;38(4):797-803
49. Donohue JF, Fogarty C, Lötvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010;182(2):155-62
50. Decramer ML, Chapman KR, Dahl R, et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med 2013;1(7):524-33
51. Donohue JF, Singh D, Kornmann O, et al. Safety of indacaterol in the treatment of patients with COPD. Int J Chron Obstruct Pulmon Dis 2011;6:477-92
52. 2-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest 2011;140(1):68-75
53. Hanania NA, Feldman G, Zachgo W, et al. The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial. Chest 2012;142(1):119-27
54. Kerwin EM, Scott-Wilson C, Sanford L, et al. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD. Respir Med 2013;107(4):560-9
55. Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med 2013;1(3):210-23
56. Bouyssou T, Casarosa P, Naline E, et al. Pharmacological characterization of olodaterol, a novel inhaled beta2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models. J Pharmacol Exp Ther 2010;334:53-62
57. Casarosa P, Kollak I, Kiechle T, et al. Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol. J Pharmacol Exp Ther 2011;337:600-9
58. Lange P, Aumann J-L, Derom E, et al. The 24-h FEV1 time profile of olodaterol QD delivered via Respimat® in COPD: results from two 6-week studies. ERS meeting 2013 oral presentation 4635
59. Ferguson GT, Feldman GJ, Hofbauer P, et al. Lung function efficacy of olodaterol QD delivered via Respimat® in COPD patients: results from two 48-week studies. ERS meeting 2013 oral presentation 186
60. Koch A, Pizzichini E, Hamilton A, et al. Lung function efficacy of olodaterol QD delivered via Respimat® vs. placebo and formoterol BID in patients with COPD: two 48-week studies. ERS meeting 2013 poster no. P764
61. Koch A, Paggiaro P, Hamilton A, et al. Symptomatic benefit of olodaterol QD delivered via Respimat® vs. placebo and formoterol BID in patients with COPD: combined analysis from two 48-week studies. ERS meeting 2013 poster no. P763
62. McGarvey L, Koch A, Sachs P, et al. 48-week administration of olodaterol QD via Respimat® vs. placebo and formoterol BID in patients with COPD: pooled safety analysis. ERS meeting 2013 poster no. P3633
63. Kikkawa H, Kanno K, Ikezawa K. TA-2005, a novel, long-acting and selective beta2-adrenocepter agonist: characterization of its in vivo bronchodilating action in guinea pigs and cats in comparison with other beta2-agonists. Biol Pharm Bull 1994;17:1047-52
64. Cazzola M, Segreti A, Matera MG. Novel bronchodilators in asthma. Curr Opin Pulm Med 2010;16(1):6-12
65. Make BJ, Kanniess F, Bateman ED, et al. Efficacy of 3 different doses of carmoterol, a long-acting 2-agonist in patients with COPD. Proc Am Thorac Soc 2008;5:A961
66. Bateman ED. Carmoterol - safety and tolerability of a long-acting β2 agonist in patients with COPD. Proc Am Thorac Soc 2008;5:A653
67. Nielsen JC, Hutmacher MM, Cleton A, et al. Longitudinal FEV1 dose-response model for inhaled PF-00610355 and salmeterol in patients with chronic obstructive pulmonary disease. J Pharmacokinet Pharmacodyn 2012;39:619-34
68. Diderichsen PM, Cox E, Martin SW, et al. Predicted heart rate effect of inhaled PF-00610355, a long acting beta-adrenoceptor agonist, in volunteers and patients with chronic obstructive pulmonary disease. Br J Clin Pharmacol 2013;76(5):752-62
69. Glossop PA, Lane CA, Price DA, et al. Inhalation by design: novel ultra-long-acting β(2)-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup. J Med Chem 2010;53(18):6640-52
70. Cazzola M, Calzetta L, Matera MG. beta (2)-adrenoreceptor agonists: current and future direction. Br J Pharmacol 2011;163(1):4-17
71. Li GL, Mac Intyre F, Surujbally B, et al. Pharmacokinetics of PF-00610355, a novel inhaled long-acting beta2-adrenoreceptor agonist [abstract]. Eur Respir J 2009;34:777s
72. Macintyre F, Jones I, Surujbally B. A randomised, double-blind study to determine the duration of action of lung pharmacodynamics by plethysmo plethysmography (sGaw) of a beta2 adrenoreceptor agonist, PF-00610355 [abstract]. Eur Respir J 2009;34:344s
73. Aparici M, Gómez-Angelats M, Vilella D, et al. Pharmacological characterization of abediterol, a novel inhaled beta(2)-adrenoceptor agonist with long duration of action and a favorable safety profile in preclinical models. J Pharmacol Exp Ther 2012;342(2):497-509
74. Beier J, Pujol H, Seoane B, et al. Efficacy and safety of abediterol (LAS100977) in patients with COPD: Phase II, randomised, crossover study. ERS meeting 2013 oral presentation 183
75. Kuna P, Ivanov Y, Trofimov VI, et al. Efficacy and safety of AZD3199 vs formoterol in COPD: a randomized, double-blind study. Respir Res 2013;14:64
76. Malerba M, Radaeli A, Morjaria JB. Therapeutic potential for novel ultra long-acting beta2-agonists in the management of COPD: biological and pharmacological aspects. Drug Discov Today 2012;17(9-10):496-504
77. Deaths: preliminary Data for 2011. Centers for Disease Control and Prevention (CDC). Available from: http://www.cdc.gov/nchs/fastats/deaths. htm [Last accessed 12 May 2014]
78. Decramer ML, Hanania NA, Yawn BP, et al. The safety of long-acting beta2-agonists in the treatment of stable chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2013;8:53-64
79. Wang J, Nie B, Xiong W, et al. Effect of long-acting beta-agonists on the frequency of COPD exacerbations:a meta-analysis. J Clin Pharm Ther 2012;37:204-11
80. Suissa S, Ernst P, Vandemheen KL, et al. Methodological issues in therapeutic trials of COPD. Eur Respir J 2008;31:927-33
81. Rogers DF. Mucociliary dysfunction in COPD: effect of current pharmacotherapeutic options. Pulm Pharmacol Ther 2005;18:1-8
82. 2 long-acting and anticholinergic drugs control TGF-beta1-mediated neutrophilic inflammation in COPD. Biochim Biophys Acta 2012;1822(7):1079-89
83. Tashkin DP, Fabbri LM. Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res 2010;11:149
84. Vestbo J, Anderson JA, Calverley PM, et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax 2009;64(11):939-43
85. Friedman HS, Navaratnam P, McLaughlin J. Adherence and asthma control with mometasone furoate versus fluticasone propionate in adolescents and young adults with mild asthma. J Asthma 2010;47(9):994-1000
86. Navaratnam P, Friedman HS, Urdaneta E. Treatment with inhaled mometasone furoate reduces short-acting beta(2) agonist claims and increases adherence compared to fluticasone propionate in asthma patients. Value Health 2011;14(2):339-46
87. Bae JP, Dobesh PP, Klepser DG, et al. Adherence and dosing frequency of common medications for cardiovascular patients. Am J Manag Care 2012;18(3):139-46
88. Incorvaia C, Ridolo E, Riario-Sforza E, et al. Indacaterol in the treatment of chronic obstructive pulmonary disease: from clinical trials to daily practice. Rev Recent Clin Trials 2014. [Epub ahead of print]
89. Beeh KM, Wagner F, Khindri S, et al. Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD. COPD 2011;8(5):340-5
90. Zafar MA, Tsuang W, Lach L, et al. Dynamic hyperinflation correlates with exertional oxygen desaturation in patients with chronic obstructive pulmonary disease. Lung 2013;191(2):177-82
91. Salpeter SR, Thomas TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD. Chest 2004;125:2309-21
92. Khindri S, Sabo R, Harris S, et al. Cardiac safety of indacaterol in healthy subjects: a randomized, multidose, placebo- and positive-controlled, parallel-group thorough QT study. BMC Pulm Med 2011;11:31
93. Huiart L, Ernst P, Suissa S. Cardiovascular morbidity and mortality in COPD. Chest 2005;128(4):2640-6
94. Sin DD, Wu L, Man SF. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest 2005;127(6):1952-9
95. Hawkins NM, Wang D, Petrie MC, et al. Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. Eur J Heart Fail 2010;12:557e65
96. Au DH, Udris EM, Fan VS, et al. Risk of mortality and heart failure exacerbations associated with inhaled beta-adrenoceptor agonists among patients with known left ventricular systolic dysfunction. Chest 2003;123(6):1964-9
97. Hawkins NM, Petrie MC, Macdonald MR, et al. Heart failure and chronic obstructive pulmonary disease the quandary of beta-blockers and beta-agonists. J Am Coll Cardiol 2011;57(21):2127-38
98. Mentz RJ, Fiuzat M, Kraft M, et al. Bronchodilators in heart failure patients with COPD: is it time for a clinical trial?J Card Fail 2012;18(5):413-22
99. Chung VC, Ma PH, Hui DS, et al. Indacaterol for chronic obstructive pulmonary disease: systematic review and meta-analysis. PLoS One 2013;8(8):e70784
100. Cope S, Donohue JF, Jansen JP, et al. Comparative efficacy of long-acting bronchodilators for COPD - a network meta-analysis. Respir Res 2013;14:100
101. Vogelmeier C, Kardos P, Harari S, et al. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med 2008;102:1511-20
102. Donohue JF. Minimal clinically important differences in COPD lung function. COPD 2005;2:111-24
103. Jones PW. St. George's Respiratory Questionnaire: MCID. COPD 2005;2:75-9
104. Schünemann HJ, Puhan M, Goldstein R, et al. Measurement properties and interpretability of the Chronic Respiratory Disease Questionnaire (CRQ). COPD 2005;2:81-9
105. Kupferberg DH, Kaplan RM, Slymen DJ, et al. Minimal clinically important difference for the UCSD Shortness of Breath Questionnaire. J Cardiopulm Rehabil 2005;25:370-7
106. Mahler DA, Witek TJ Jr. The MCID of the transition dyspnea index is a total score of one unit. COPD 2005;2:99-103
107. Ries AL. Minimally clinically important difference for the UCSD Shortness of Breath Questionnaire, Borg Scale, and Visual Analog Scale. COPD 2005;2:105-10
108. Polkey MI, Spruit MA, Edwards LD, et al. Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization. Am J Respir Crit Care Med 2013;187(4):382-6